Zenotech Laboratories Past Earnings Performance
Past criteria checks 2/6
Zenotech Laboratories has been growing earnings at an average annual rate of 25.6%, while the Biotechs industry saw earnings growing at 10.3% annually. Revenues have been growing at an average rate of 17.1% per year. Zenotech Laboratories's return on equity is 9.2%, and it has net margins of 22%.
Key information
25.6%
Earnings growth rate
25.8%
EPS growth rate
| Biotechs Industry Growth | 5.1% |
| Revenue growth rate | 17.1% |
| Return on equity | 9.2% |
| Net Margin | 22.0% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Zenotech Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 378 | 83 | 95 | 0 |
| 31 Dec 23 | 391 | 113 | 89 | 0 |
| 30 Sep 23 | 368 | 93 | 85 | 0 |
| 30 Jun 23 | 372 | 100 | 82 | 0 |
| 31 Mar 23 | 390 | 116 | 79 | 0 |
| 31 Dec 22 | 370 | 220 | 77 | 0 |
| 30 Sep 22 | 383 | 243 | 75 | 0 |
| 30 Jun 22 | 356 | 225 | 73 | 0 |
| 31 Mar 22 | 329 | 222 | 71 | 0 |
| 31 Dec 21 | 319 | 92 | 70 | 0 |
| 30 Sep 21 | 273 | 57 | 69 | 0 |
| 30 Jun 21 | 233 | 27 | 67 | 0 |
| 31 Mar 21 | 194 | -12 | 65 | 0 |
| 31 Dec 20 | 178 | -24 | 60 | 0 |
| 30 Sep 20 | 197 | 44 | 61 | 0 |
| 30 Jun 20 | 239 | 85 | 60 | 0 |
| 31 Mar 20 | 259 | 108 | 58 | 0 |
| 31 Dec 19 | 253 | 134 | 58 | 0 |
| 30 Sep 19 | 224 | 56 | 54 | 0 |
| 30 Jun 19 | 179 | 12 | 51 | 0 |
| 31 Mar 19 | 130 | -31 | 50 | 0 |
| 31 Dec 18 | 111 | -73 | 49 | 0 |
| 30 Sep 18 | 109 | -78 | 51 | 0 |
| 30 Jun 18 | 107 | -91 | 51 | 0 |
| 31 Mar 18 | 111 | -119 | 51 | 0 |
| 31 Dec 17 | 101 | -143 | 49 | 0 |
| 30 Sep 17 | 70 | -181 | 43 | 0 |
| 30 Jun 17 | 47 | -196 | 35 | 0 |
| 31 Mar 17 | 23 | -199 | 31 | 0 |
| 31 Dec 16 | 6 | -202 | 15 | 0 |
| 30 Sep 16 | 7 | -197 | 22 | 0 |
| 30 Jun 16 | 15 | -195 | 34 | 0 |
| 31 Mar 16 | 21 | -191 | 23 | 0 |
| 31 Dec 15 | 28 | -249 | 2 | 0 |
| 30 Sep 15 | 31 | -313 | 26 | 0 |
| 30 Jun 15 | 33 | -308 | 26 | 0 |
| 31 Mar 15 | 41 | -201 | 33 | 0 |
| 31 Mar 14 | 28 | -271 | 62 | 15 |
Quality Earnings: 532039 has high quality earnings.
Growing Profit Margin: 532039's current net profit margins (22%) are lower than last year (29.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 532039 has become profitable over the past 5 years, growing earnings by 25.6% per year.
Accelerating Growth: 532039's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 532039 had negative earnings growth (-28.4%) over the past year, making it difficult to compare to the Biotechs industry average (-0.8%).
Return on Equity
High ROE: 532039's Return on Equity (9.2%) is considered low.